Key Developments: Terumo Corp (4543.T)
24 May 2013
Latest Key Developments (Source: Significant Developments)
Terumo Corporation announced that it has decided to retire 20,996,000 shares (9.96% stake) of its common stock, effective November 10, 2011. After the stock retirement, the total share outstanding will become 189,880,260. Full Article
Terumo Corporation announced that it has raised the consolidated mid-year outlook for revenue from JPY 157,000 million to JPY 191,000 million, operating profit from JPY 30,000 million to JPY 32,700 million, ordinary profit from JPY 29,000 million to JPY 31,500 million, but has reaffirmed the consolidated mid-year outlook for net profit at JPY 18,500 million and earning per share at JPY 97.43 for the fiscal year ending March 31, 2012. The Company has also raised the consolidated full-year outlook for revenue from JPY 332,000 million to JPY 390,000 million, operating profit from JPY 65,000 million to JPY 67,000 million, ordinary profit from JPY 63,000 million to JPY 65,000 million, but has lowered the consolidated full-year outlook for net profit at JPY 40,000 million to JPY 38,500 million and earning per share from JPY 210.66 to JPY 202.76 for the fiscal year ending March 31, 2012. The Company amended the mid-year and full-year outlook due to the revaluation of two newly acquired companies, CaridianBCT and Harvest Technologies. Full Article
R&I Affirms Rating on Terumo Corporation at "AA-"; Removed Terumo Corporation from Rating Monitor; Rating Outlook Negative
Rating and Investment Information, Inc. (R&I) announced that it has reaffirmed the rating on Terumo Corporation at "AA-". R&I has removed Terumo Corporation from rating monitor. The rating outlook is negative. Full Article
- A drug-coated heart stent from Japan's Terumo Corp with a dissolving polymer proved just as effective as Abbott Laboratories' top-selling Xience stent at preventing a second procedure to clear the artery, a large study found.